share_log

Wells Fargo Maintains Overweight on Abbott Laboratories, Lowers Price Target to $116

Benzinga ·  Oct 19, 2023 09:36

Wells Fargo analyst Lawrence Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $136 to $116.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment